| Identification | Back Directory | [Name]
1,3-Dioxolo[4,5-g]furo[3,4-b]quinolin-8(5H)-one, 9-(3-fluorophenyl)-6,9-dihydro-5-(2-hydroxyethyl)- | [CAS]
2376580-08-2 | [Synonyms]
SU056
1,3-Dioxolo[4,5-g]furo[3,4-b]quinolin-8(5H)-one, 9-(3-fluorophenyl)-6,9-dihydro-5-(2-hydroxyethyl)- | [Molecular Formula]
C20H16FNO5 | [MOL File]
2376580-08-2.mol | [Molecular Weight]
369.34 |
| Chemical Properties | Back Directory | [Boiling point ]
577.4±50.0 °C(Predicted) | [density ]
1.53±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
14.61±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
SU056 is a YB-1 inhibitor. SU056 induces cell-cycle arrest, apoptosis, and inhibits cell migration in ovarian cancer cells. SU056 interacts with YB-1 and inhibits and its associated downstream proteins and pathways. SU056 can enhance the cytotoxic effects of Paclitaxel (HY-B0015)[1]. | [in vivo]
SU056 (20 mg/kg, i.p.) inhibits tumor growth in mice implanted with ID8 cells[1].
SU056 (10 mg/kg, i.p., daily) combined with Paclitaxel (HY-B0015) (5 mg/kg, weekly, i.p.) shows a much greater reduction in OC tumor growth in immunodeficiency mice implanted with OVCAR8 OC tumors[1].
| Animal Model: | C57BL/6 mice implanted (s.c.) with luciferase-expressing ID8 cells[1] | | Dosage: | 20 mg/kg | | Administration: | Intraperitoneal injection (i.p.) | | Result: | Reduced the tumor weight by 2-fold, and is well-tolerated.
Reduced the lung metastases.
Inhibited YB-1 expression and downstream MDR1 (IHC assay of tumor sample).
|
| [References]
[1] Tailor D, et al. Y box binding protein 1 inhibition as a targeted therapy for ovarian cancer. Cell Chem Biol. 2021 Aug 19;28(8):1206-1220.e6. DOI:10.1016/j.chembiol.2021.02.014 |
|
|